Commission authorises treatment for metastatic pancreatic cancer to address an unmet medical need

Today, the European Commission granted EU marketing authorisation for Daraxonrasib, a new treatment for metastatic pancreatic cancer. It can be used to treat adults that have already undergone at least one previous round of treatment.

This new cancer medicine was subject to accelerated regulatory procedures, foreseen under the EU pharmaceutical reform, without compromising the EU's rigorous safety, quality and efficacy standards. This included a phased review by the European Medicines Agency (EMA), which delivered a positive scientific assessment in just over 100 days, nearly half the length of time of the previous legal deadline of 210 days. The newly authorised medicine could address an unmet medical need as it targets a serious disease for which there is a need for better treatment options. For this reason, it was named as a high-priority medicine in the EMA's Cancer Medicines Pathfinder.

Daraxonrasib is also subject to an ongoing joint clinical assessment (JCA) by the Member State Coordination Group on Health Technology Assessment. Joint clinical assessments allow EU Member States to work together to evaluate the clinical benefits of new medicines and certain medical devices by reducing duplication, saving time and resources, and giving companies a clearer and more predictable process. The preparation of the JCA report is being accelerated to be available in December in order to facilitate access across the EU.

The Commission decision will be available soon online.

(For more information: Eva Hrnčířová – Tel.: +32 2 298 84 33; Anna Gray – Tel.: +32 2 298 08 73)


Zařazenoút 17.11.2026 12:11:15
Vydáno
ZdrojEvropská komise en
Originálec.europa.eu/commission/presscorner/api/documents?reference=MEX/26/2471&language=en&ord=4
langen
guid/MEX/26/2471/#4

Související témata

X 
Zobrazit sloupec